{"disease":{"id":"primary-glioblastoma-multiforme","name":"primary glioblastoma multiforme"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04250922","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Laminar Pharmaceuticals","has_results":false},{"nct_id":"NCT07391215","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT06632236","title":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}